Loading Results
We have updated our Online Services Terms of Use and Privacy Policy. See our Cookies Notice for information concerning our use of cookies and similar technologies. By using this website or clicking “I ACCEPT”, you consent to our Online Services Terms of Use.

Pediatric Patients Aged 1 to 6 Years With APDS

An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients (Aged 1 to 6 Years) with APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome) Followed by an Open-label Long-term Extension

dna strands

 

AGE: 1 - 6 years old
SEX AT BIRTH: All
HEALTHY PARTICIPANTS: No
TYPE: Interventional Drug Study
CONDITION: Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS)
LOCATION:University Hospitals Rainbow Babies and Children’s, University Hospitals Cleveland Medical Center

Learn More About This Research Study

For more information, please contact study coordinator, Erica Denallo at 216-286-7453 or complete the form below.

Study Purpose

The purpose of this research study is to find out how well the investigational study drug leniolisib is tolerated and the efficacy of leniolisib for the treatment of APDS (Activated Phosphoinositide 3-Kinase Delta Syndrome). This is a 2-part study and includes a screening period (up to 7 weeks), a treatment period of Part I (up to 12 weeks), a treatment period of Part II (up to 52 weeks), and a follow-up period (up to 4 weeks). If your child completes the study, he or she will participate for a total of 75 weeks and visit the study site around 11 times. The duration of the appointment will vary according on the procedures conducted.

Who Can Participate

Participants between the ages of 1 and 6 who are diagnosed with Activated Phosphoinositide 3-Kinase Delta Syndrome may be eligible to participate.

I'm not a robot

Study ID